It is the first biosimilar of a rapid-acting insulin product – used to control the blood glucose spike after meals – and only the third insulin biosimilar to be approved in the US.

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 were able to come off insulin within a year.